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One Sentence Summary: Small subpopulations of genetic mutants that become fixed after selection are visible in the original culture of a Mycobacterium
tuberculosis laboratory strain.
Editor: David Studholme
ABSTRACT
We studied genomic variation in a previously selected collection of isogenic Mycobacterium tuberculosis laboratory strains
subjected to one or two rounds of antibiotic selection. Whole genome sequencing analysis identified eleven single, unique
mutations (four synonymous, six non-synonymous, one intergenic), in addition to drug resistance-conferring mutations,
that were fixed in the genomes of six monoresistant strains. Eight loci, present as minority variants (five non-synonymous,
three synonymous) in the genome of the susceptible parent strain, became fixed in the genomes of multiple daughter
strains. None of these mutations are known to be involved with drug resistance. Our results confirm previously observed
genomic stability for M. tuberculosis, although the parent strain had accumulated allelic variants at multiple locations in an
antibiotic-free in vitro environment. It is therefore likely to assume that these so-called hitchhiking mutations were
co-selected and fixed in multiple daughter strains during antibiotic selection. The presence of multiple allelic variations,
accumulated under non-selective conditions, which become fixed during subsequent selective steps, deserves attention.
The wider availability of ‘deep’ sequencing methods could help to detect multiple bacterial (sub)populations within patients
with high resolution and would therefore be useful in assisting in the detailed investigation of transmission chains.
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INTRODUCTION
Drug-resistant Mycobacterium tuberculosis, the causative agent
of tuberculosis (TB), is an increasing problem that is severely
complicating effective treatment of the otherwise curable dis-
ease. Multidrug-resistant TB (MDR-TB) is caused by M. tu-
berculosis bacilli that are by definition resistant to first-line
drugs rifampicin and isoniazid. Resistance in M. tuberculosis is
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predominantly conferred by genomic mutations and MDR
strains typically carry resistance-mediating mutations in rpoB,
conferring resistance to rifampicin, and in katG, conferring resis-
tance to isoniazid (Musser 1995; Ramaswamy and Musser 1998).
Resistance mutations can impair bacterial fitness which may
affect survival within the host and onward transmission (Co-
hen, Sommers and Murray 2003; Mariam et al., 2004; Gagneux
et al., 2006; Luciani et al., 2009). Some evidence is available that
resistant mutants can restore this fitness loss by the acquisition
of adaptive mutations (Sherman et al., 1996; Casali et al., 2012,
2014; Comas et al., 2012).
Mycobacterium tuberculosis is a monomorphic organism with
no evidence of horizontal transfer of genetic elements and a low
recombination rate (Sreevatsan et al., 1997; Brosch et al., 2002;
Smith et al., 2006, 2009; Gagneux and Small 2007; Achtman 2008);
within the members of the M. tuberculosis complex (M. tubercu-
losis, M. bovis, M. africanum, M. microti and M. pinnipedii), there
is a genomic resemblance of >99%. The population structure of
M. tuberculosis furthermore suggests that phylogenetic lineages,
which can be distinguished on the basis of few genetic mark-
ers (Coll et al., 2014), have co-evolved with and adapted to their
respective hosts (Caws et al., 2008).
Typing ofM. tuberculosis strains is commonly achieved by one
or a combination of the following methods: RFLP, CRISPR typ-
ing, VNTR/MLVA, MLST or SNP typing. The latter has been gain-
ing popularity, as it is particularly appropriate for the classifica-
tion of a monomorphic organism such as M. tuberculosis, is less
prone to homoplasies and is compatible with other sequence-
based tools, such aswhole genome or deep sequencing.With the
cost of next-generation sequencing methods dropping rapidly
and their availability increasing, many researchers have used
these tools to study the micro-evolution of M. tuberculosis iso-
lates. Genomic analysis ofM. tuberculosis isolates recovered from
patients has shown that, even over longer periods of time, the
genome of the pathogen remains relatively conserved (Schu¨rch
et al., 2010). Likewise, after transmission or selection for antibi-
otic resistance, minimal genetic variability has been detected
(Niemann et al., 2009; Ford et al., 2011, 2012; Saunders et al., 2011;
Casali et al., 2012, 2014; Comas et al., 2012; Bryant et al., 2013;
Clark et al., 2013; ), although in some cases an (initial) increased
level of genetic divergence has been observed for drug resistance
mutations (Mariam et al., 2011).
The evolution of M. tuberculosis is probably most accurately
elucidated by genomic analysis of sequential isolates from a
single patient or a transmission chain. However, as there may
be multiple mycobacterial foci within a single patient, each be-
ing subjected to severe sequential bottlenecks,multiplemutants
may emerge simultaneously within the patient. Thus, sequenc-
ing single isolates may dramatically overestimate the relative
prevalence and likelihood of particular mutations and under-
estimate the dynamics of traits under evolution or very strong
selection, such as drug resistance. A recent study focusing on
the emergence of quinolone resistance within the host has in-
deed shown that multiple resistance-associated mutations can
occur inside one patient and that the distribution of these mu-
tants can vary significantly between sequential isolates (Stre-
icher et al., 2012).
We investigated the in vitro evolution of a collection of well-
characterized isogenic drug-resistant mutants after antibiotic
selection on solid medium by whole genome sequencing. Our in
vitro findings corroborate data from previous studies where clin-
ical isolates under evolution show a similar degree of genomic
stability (Schu¨rch et al., 2010; Ford et al., 2011; Mariam et al., 2011;
Bryant et al., 2013; Clark et al., 2013). Additionally, in the major-
ity of the strains studied we also found evidence of hitchhiking
mutations that were present as minority variants in the parent
strain, as well as fixation of additional mutations not associated
with drug resistance. On the basis of these signature mutations
a phylogenetic relationship could be inferred between all strains
included in this study. We believe that this illustrates the great
potential of whole genome sequencing analysis, in particular
deep sequencing identifying minority variants, to aid investiga-
tions on patient-to-patient transmission of M. tuberculosis, par-
ticularly when clinical or epidemiological data is missing or in-
complete.
METHODS
Strains
Drug-resistant mutants used in this study were all derived from
a cultivar of the M. tuberculosis laboratory strain MTB72 (ATCC
35801) which has been propagated in our laboratory for more
than 20 years and is susceptible to all commonly used anti-TB
drugs. All strains are derived from experiments that have been
previously described (Anthony et al., 2005; Bergval et al., 2007;
Bergval et al., 2009).
Culture and selection of mutants
Spontaneous mutants were selected in 2003/2004 [R, B and RB
strains, Fig. 1 and Anthony et al. (2005)] or 2006 [H strains, Fig. 1
and Bergval et al. (2009)] from a liquid culture from MTB72, by
plating an aliquot from a log-phase MTB72 culture (ca. 3 weeks,
108 CFU) onto antibiotic-containing solid medium. Strains R4,
R46, R181 and R190 were selected with 8 μg mL−1 rifampicin,
strains R181 and R190 in a different experiment and with a dif-
ferent starting culture of MTB72, but in the same month. Strain
B15was selectedwith 8μgmL−1 rifabutin and strain B66with 0.8
μg mL−1 rifabutin in two different experiments using two start-
ing cultures from MTB72 over a period of two months. The ri-
fampicin MIC and the rifabutin MIC was previously determined
for all rifampicin-resistant strains (Anthony et al., 2005); R190
showed resistant to rifampicin (32 μg mL−1), but susceptible to
rifabutin (<0.8 μgmL−1), which allowed us to subject strain R190
to a second round of selection (Fig. 1). Strains RB14, RB15, RB16
and RB19 are spontaneous, double-resistant, mutants derived
from strain R190 selected by plating an aliquot from an R190 liq-
uid culture onto solid medium containing 2 μg mL−1 rifabutin.
Strains H15 (March 2006), H71 (August 2006) and H103
(November 2006) are selected by 20 μg mL−1 (H15 and H71) and
0.4 μg mL−1 (H103) isoniazid; in the case of H71, the parent cul-
ture was treated with hydrogen peroxide before an aliquot was
plated on selective medium (Bergval et al., 2009). The strains
were selected in three different experiments, using three differ-
ent starting cultures of MTB72.
Genetic analysis
For all mutants, the mutation responsible for resistance to
drug(s) in question was determined via Sanger sequencing (An-
thony et al., 2005; Bergval et al., 2009); two regions of rpoB were
analysed for strains resistant to rifampicin and/or rifabutin for
the isoniazid-resistant strains parts of the mabA-inhA inter-
genic region and of katG, known to contain mutants in clini-
cal isolates, were analysed. Before sequencing the associated
genes, the isoniazid-resistant strains were first assessed by
an adapted multiplex ligation-dependent probe amplification
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Figure 1. Relationship and selection conditions of strains used in this study. MTB72 is the parent strain to all first-step monoresistant mutants. During seven separate
experiments, nine isogenic mutants were selected on solid medium containing the concentrations of antibiotic depicted on the left side of the boxes. Each color
indicates a different experiment. The boxes indicate the strain name (solid color) and the identified resistance-conferring mutation it carries (blank box with colored
outline). Strain R190 was subjected to a second round of selection, from which the four strains (RB14-RB19) depicted on the right are derived. The mutations indicated
in these boxes are in addition to the mutation that was acquired by R190. RIF: rifampicin, RBT: rifabutin, INH: isoniazid, H2O2: hydrogen peroxide.
assay, to determine if a deletion in or of katG was present
(Bergval et al., 2009).
The genomes of strains MTB72 and R190 were previ-
ously analysed by comparative genome hybridization (Bergval
et al., 2009).
Whole genome sequencing and analysis of genetic
variants
DNA isolation and sequencing
For each strain, DNAwas extracted via the cetyltrimethylammo-
nium bromide procedure (Soolingen et al., 1991) from 1 mL of a
logarithmic phase liquid culture (ca. 3 weeks growth) (Anthony
et al., 2005; Bergval et al., 2009). The DNA concentration of the
samples used in this study was between 53 and 142 ng mL DNA,
as determinedwith theNanoDrop (Thermo Fisher Scientific Inc.,
Wilmington, Delaware, USA). The sequencing was carried out at
the KAUST Genomics Facility, using Illumina HiSeq 2000 tech-
nology with paired-end reads of length 100 base pairs.
Data analysis
Trimmomatic software (Bolger, Lohse andUsadel 2014) was used
to remove low-quality reads and trim low-quality 3′ ends of
reads. Nucleotide positions in the raw reads with a quality score
lower than Q20 were removed. High-quality reads were then
mapped to the H37Rv reference genome (Camus et al., 2002)
(Genbank accession: AL123456.3) using the BWA-memalgorithm
(Li 2014). SAMtools (Li et al., 2009) and GATK (DePristo et al., 2011)
were used to call SNPs. SNP sites were then selected as the in-
tersection dataset between those obtained from both programs.
Polymorphic sites at non-unique regions of the genome (Der-
rien et al., 2012) were filtered out. The depth of coverage was
calculated from alignment files using a custom Perl script. For
each sample, SNP genotypes were called if supported by at least
20-fold total coverage, otherwise they were classified as miss-
ing. The read depth and coverage of all variants identified in all
strains included in this study are depicted in Fig. S1 (Supporting
Information). Multiple genotypes were allowed by adding alleles
supported by at least 5% of total number of reads. We excluded
positions in the genome withmore than 20%missing genotypes
across all samples. In the final dataset, we retained 912 SNP sites,
83% (912/1096) of the original SNP sites derived using SAMtools
and GATK. Artemis (Rutherford et al., 2000) was used to verify
these variants in the BAM files and to determine the read depth.
All sequences have been deposited to Sequence Read Archive
(http://trace.ncbi.nlm.nih.gov/Traces/sra/), NCBI’s repository for
high-throughput sequencing data and are publicly available un-
der accession number SRP049364.
RESULTS
Our collection of isogenic mutants included a pansusceptible
parent strain (MTB72), nine first-generation (single-step) drug-
resistant daughter strains and four second-generation (two-
step) daughter strains (Fig. 1). The nine monoresistant strains
that were directly derived from MTB72 by a single round of an-
tibiotic selection (R-, B- and H-series, Fig. 1) all acquired at least
one additional mutation in a gene not directly associated with
drug resistance (Table 1).
A total of 21 non-drug resistance mutations were detected,
eight of which were identified in multiple daughter strains.
Interestingly, these eight alleles present in multiple daughter
strains could already be detected in the genome of the parent
strain (indicated as mixed alleles in Table 1). Themutations that
could be detected in the parent strain show various linkage pat-
terns: mutations in ctpV, Rv1215c, ceoB and Rv2693c are shared
by strains R4, R46, R181, R190 (and offspring) and B66; mutations
in dnaB, ispE and gcvB are shared by strains R46 and B66; themu-
tation in ilvA is shared by H15, H71 and H103 (Table 1).
Eleven mutations were uniquely found in six strains
and could not be detected in the genome of the par-
ent strain: R4 (hycQ-T138T, zwf1-R136C, murF-A501V), R181
(lppY-G97R), R190 (dnaA-V270I, Rv0466-S93S, shared with off-
spring: zmp1-D637D, Rv1215c-M243I), B15 (Rv2974c-L251L), H103
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Figure 2. Inferred phylogeny of strains used in this study. Colors of boxes refer
to selection procedures explained in Fig. 1 and the section ‘Methods’. The phy-
logenetic tree is based on the following assumptions: (1) mutational events a, i
and n occurred only once, (2) they occurred in the culture of the parent strain
MTB72 before antibiotic selection and (3) the dominant allele observed in the
MTB72 sample is the wild-type (or baseline) sequence. Branches are based on
the following mutational events (a more detailed description of each mutation
can be found in Table 1): a. ctpV-38, Rv1674c-55, ceoB-55, Rv2693c-24; b. zmp1–
637, Rv1215c-243, rpoB-522; c. dnaA-270, Rv0466–93; d. rpoB-176; e. rpoB-178;
f. rpoB-531; g. rpoB-531; h. hycQ-138, zwf1–136, murF-501, rpoB-526; i. dnaB-765,
ispE-75, gcvB-521; j. rpoB-531; k. rpoB-531; l. lppY-97, rpoB-526; m. Rv2974c-251,
rpoB-525–527; n. ilvA-85; o. crp-142, pks2–512, katG-321; p. Rv3446c-241, katG-
384; q. wag22-Rv1760-(-)63, katG-271.
(wag22-Rv1760-A(-)63G) and H71 (Rv3446c-V241I) (Table 1).
These singletons were fixed in the genomes of the strains carry-
ing them; no other alleles could be detected [see Table S1 (Sup-
porting Information) for coverage and read depth of all variants].
Six out of eleven mutations were non-synonymous (highlighted
in blue, Table 1), four were synonymous and one was intergenic.
The mutations in crp and pks2 observed in H15 (Table 1) were
accompanied by the wild-type allele which indicates that these
variantswere acquired inH15 post antibiotic selection. Bothmu-
tations are non-synonymous and the percentages of both mu-
tant alleles were higher than the corresponding wild-type al-
lele; the allelic distributions detected in H15 were 14/0/0/52 and
0/40/0/9 versus 111/0/0/0 and 0/0/0/59 in MTB72 for crp and pks2,
respectively (order of the bases A/C/G/T).
One of the first-generation mutants, R190, was subjected to
a second round of selection with rifabutin and four of its daugh-
ter strains (RB14, RB15, RB16 and RB19), with double rpoB mu-
tations, were also included in this study (Fig. 1). Strain R190 ac-
quired, in addition to the rpoB-S522L mutation associated with
rifampicin resistance, four unique mutations (in dnaA, zmp1,
Rv1215c and Rv0466, Table 1), two of which were absent in its
offspring (dnaA-V270I and Rv0466-S93S), illustrating that these
mutations were acquired and/or selected for after the daughter
strains were selected. No additional mutations apart from those
associated with rifabutin resistance were identified in the four
daughter strains of R190.
Based on the data acquired by whole genome analysis, we
inferred a phylogenetic tree (Fig. 2), using the data on drug resis-
tance mutations to resolve the branches in the cases where this
was necessary (e.g. the rpoB-S531Lmutationwhichwas acquired
separately by four different strains). This tree is highly similar to
the evolution assumed on the basis of our experimental proce-
dure (Fig. 1), with the exception of strain B66 that showed to be
more related to the R strains (namely R46, Fig. 2) than we an-
ticipated. Most branches are represented by two or more muta-
tional events, since it was not possible to determine the exact
order and timing for each mutation separately.
DISCUSSION
The population structure of M. tuberculosis is highly clonal,
with all phylogenetic members sharing more than 99% of their
genome sequence. Genomic studies have found that epidemi-
ologically linked strains, extracted from (patient-to-patient)
transmission chains (Schu¨rch et al., 2010; Bryant et al., 2013; Clark
et al., 2013; Torok et al., 2013) or within the patient (Saunders
et al., 2011; Sun et al., 2012), are genetically stable with esti-
matedmutation rates of 0.3–0.5 SNPs/year in low-endemic areas
(Bryant et al., 2013; Walker et al., 2013).
We have analysed the genomes of an isogenic collection of in
vitro selected drug-resistant strains to determine if mutations,
other than those conferring drug resistance, had accumulated
during selection or cultivation. Our results show that during
selection, mutations not associated with drug resistance were
co-selected with the resistance trait. Some of these hitchhiking
mutations were already detectable in the genome of the parent
strain as minority variants and were likely accumulated over
time in only a discrete amount of subpopulations [Tables 1 and 2
and Fig. S2 (Supporting Information)] (Barrick and Lenski 2013).
At the loci that showed mixed alleles in the MTB72 genome
(Table 1), we assumed that the dominant allele was the origi-
nal sequence and theminority variant represented themutation
(Table 2). However, for ctpV, Rv1674c, ceoB and Rv2693c, the dom-
inant allele was different to that of the reference genome from
H37Rv; instead, the minority allele corresponded to this refer-
ence genome. It is possible that the mutant allele had become
dominant in the MTB72 culture in these specific locations. Con-
versely, the mutations at these loci in the MTB72 may have been
historical and the minority variants would therefore represent
‘back mutations’. From the data we have available, it was not
possible to determine which scenario had occurred.
None of the strains acquired amutation in rpoA or rpoC, some
of which have been suggested to compensate for the fitness
loss inflicted by rpoB mutations, particularly rpoB-S531L (Casali
et al., 2012; Comas et al., 2012). However, compared to H37Rv,
MTB72, and its entire offspring, carry an rpoC-G594E mutation.
This mutation is not associated with compensation, but is a
genotypicmarker, specific for a Euro-American sub-lineage con-
taining X and Haarlem spoligotype families (lineage 4.1 as de-
scribed in Coll et al. (2014). Although an epistatic effect on the
fitness cost of the rifampicin resistance mutations acquired of
this rpoC-G594E mutation cannot be ruled out.
We cannot be sure if the singletons observed in the genomes
of R4, R181, B15, H103, H71 and R190 (and its offspring) (Table 1)
were either co-selected and therefore pre-existing as rare vari-
ants in the MTB72 culture, or acquired post-selection. However,
the short cultivation period for these strains between selection
and sequence analysis makes it probable that these mutations
were co-selected.
The two unique mutations that were observed in strain R190
could only have been acquired after selection with rifabutin,
since none of the R190 daughter strains carried either of these
mutations. The fixation of these two post-selection mutations
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Table 2. Read depth and coverage of loci identified as mixed alleles in the parent strain. Depicted are only those loci where mutations were
acquired by at least one daughter strain and mixed alleles were observed in the parent strain MTB72. The order of the bases is A/C/G/T. Data
highlighted in bold indicates that the base was detected in >5% of the reads.
Gene/CDS dnaB ctpV ispE ilvA Rv1674c gcvB ceoB Rv2693c
Genomic position 62690 1078856 1130414 1763680 1899754 2077437 3009506 3011060
MTB72 18/0/174/0 87/0/22/0 0/78/0/3 0/1/105/0 84/0/12/0 14/0/141/0 0/5/0/71 0/11/119/0
R4 0/0/737/0 0/0/410/0 0/97/0/0 0/0/427/0 0/0/403/0 0/0/608/0 0/459/0/0 0/490/0/0
R46 816/0/0/0 0/0/479/0 0/0/0/76 0/0/489/0 0/0/524/0 536/0/0/0 0/543/0/1 0/575/0/0
R181 0/0/643/0 0/0/353/0 0/496/0/0 0/0/385/0 0/0/404/0 0/0/492/0 0/460/0/0 0/412/0/0
R190 0/0/749/0 0/0/460/0 0/47/0/0 0/0/480/0 0/0/456/0 0/0/626/0 0/499/0/0 0/533/0/0
RB14 0/0/677/0 0/0/409/0 0/514/0/0 0/0/483/0 0/0/431/0 0/0/553/0 0/446/0/0 0/497/0/0
RB15 0/0/802/0 0/0/537/0 0/324/0/0 0/0/552/0 0/0/529/0 0/0/656/0 0/568/0/0 0/589/0/0
RB16 0/0/753/1 0/0/518/0 0/477/0/0 0/0/540/0 0/0/540/0 0/0/613/0 0/527/0/0 0/647/0/0
RB19 0/0/713/0 1/0/415/0 0/363/0/0 0/0/430/0 0/0/438/0 0/0/499/0 0/446/0/0 1/475/0/0
B15 0/0/250/0 133/0/0/0 0/0/0/492 0/0/166/0 128/0/0/0 0/0/183/0 0/0/0/114 1/0/161/0
B66 203/0/0/0 0/0/96/0 0/418/0/0 0/0/136/0 0/0/120/0 183/0/0/0 0/111/0/0 0/132/0/0
H103 0/0/831/0 566/0/0/0 0/495/0/0 0/513/0/0 488/0/0/0 1/0/654/0 0/1/0/541 0/0/603/0
H15 0/0/137/0 66/0/0/0 0/500/0/0 0/50/0/0 78/0/0/0 0/0/113/0 0/0/0/52 0/0/99/0
H71 0/0/807/0 480/0/0/0 0/411/0/0 0/467/0/0 473/0/0/0 0/0/619/0 0/0/0/586 0/0/593/0
raises the possibility that one or both confer a benefit and were
under selective pressure, possibly restoring a fitness deficit re-
sulting from the rpoB-S522L mutation. This appears most likely
for the mutation in dnaA (Table 1), which is non-synonymous
and thus suggestive of a phenotypic effect.
Our findings demonstrate that there can be a detectable
amount of minority variants present in a bacterial population,
possibly reflecting the genetic diversity in (cultured) patient iso-
lates that are otherwise assumed to be largely homogenous.
Studies with Streptococcus pneumoniae also show that bacteria are
much more likely than previously anticipated to acquire muta-
tions in addition to those that confer the specific trait selected
for (Stevens and Sebert 2011). Furthermore, this concept may
have consequences for the researcher aiming to investigate sin-
gle isogenic mutants to assess their associated (in vitro) charac-
teristics, as we show here that even during a single selection
step, unintended genetic changes may be introduced. Especially
against a stable genetic background such as that ofM. tuberculo-
sis these hitchhiking mutations may be of greater influence on
the phenotype than anticipated.
Sequencing technologies that produce greater numbers of
higher quality reads of longer length increase the possibility to
detect minority variants with low copy numbers, allowing the
true genetic dynamics of a bacterial population under evolu-
tion to be studied. During patient-to-patient transmission, rigor-
ous bottlenecks can dramatically reduce the effective, net muta-
tion rate by selecting out most of the newly acquired mutations
within the bacterial populations transmitted (Sun et al., 2012).
Deep sequencing (> 500-fold coverage) therefore has the poten-
tial to be particularly appropriate to study the dynamics of M.
tuberculosis strain(s) within a single patient.
Here, we have shown that a single selection event can re-
sult in the one-step fixation of a potentially informative num-
ber of pre-existing mutations. Minority variants in clinical
isolates should thus not be ignored, as the potentially charac-
teristic signatures of these hitchhiking or co-selected mutations
in the genomes of infected strains can be used to help resolve
the details of patient-to-patient transmission.
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